Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?
There’s plenty of buzz today about Amarin $AMRN and its quest to get cardio outcomes data added to the label for Vascepa, its therapeutic strength …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
